New treatments for mitochondrial disease-no time to drop our standards

Area of Science:

• Neurology
• Genetics
• Biochemistry

Background:

• Mitochondrial dysfunction causes inherited multisystem diseases, frequently affecting the nervous system.
• Current clinical management for mitochondrial diseases is primarily supportive, despite advances in understanding pathophysiology.
• A critical need exists for improved biomarkers and robust clinical trial designs in this field.

Purpose of the Study:

• To systematically review existing literature on treatments for mitochondrial diseases.
• To identify limitations in current clinical trial methodologies and highlight publication bias.
• To provide recommendations for designing future, more reliable treatment trials.

Main Methods:

• Systematic literature search identifying 1,039 publications on mitochondrial disease treatments.
• Analysis focused on studies with observations on more than five patients.
• Evaluation of study design, outcome reporting, and potential biases.

Main Results:

• Only 35 of 1,039 reviewed studies included data on more than five patients.
• Positive outcomes reported were often based on biomarkers of unproven clinical significance.
• Nonrandomized and nonblinded studies showed a higher prevalence of positive but poorly executed results, indicating publication bias.

Conclusions:

• Existing data on mitochondrial disease treatments may be biased and unreliable.
• There is an urgent need for the development of new, clinically significant biomarkers.
• Future treatment trials must adopt rigorous designs to yield trustworthy evidence for patient care.